« Forschungslandschaft: Projekte
A prospective, randomised, controlled, open-label, multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine
Projektleiter:
Projektbearbeiter:
Michael Kreißl,
Jan Wüstemann
Finanzierung:
Industrie;
A prospective, randomised, controlled, open-label, multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-edotreotide (177Lu-DOTATOC) compared to targeted molecular therapy with everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).
Kontakt
Prof. Dr. med. Michael Kreißl
Otto-von-Guericke-Universität Magdeburg
Medizinische Fakultät
Universitätsklinik für Radiologie und Nuklearmedizin
Leipziger Str. 44
39120
Magdeburg
Tel.:+49 391 6713030
weitere Projekte
Die Daten werden geladen ...